' Twincretin ' Beats Glargine for Diabetes in Pivotal Trial ' Twincretin ' Beats Glargine for Diabetes in Pivotal Trial

The"twincretin" tirzepatide scored another pivotal-trial win in published results from the SURPASS-4 trial, which compared the investigational agent to insulin glargine for treatment of type 2 diabetes.Medscape Medical News

Source: Medscape Cardiology Headlines - October 28, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news